Skip to Main Content

Author Details

Anil K Sood
The University of Texas MD Anderson Cancer Center
1991
765
118
PMIDPaper TitleJournal TitlePublished Year
37587850Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic.J Psychosoc Oncol2024
38081436The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.Brain Behav Immun2024
38009662Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.Cancer2024
36596845Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells.Oncogene2023
37591609Low-grade serous ovarian cancer: expert consensus report on the state of the science.Int J Gynecol Cancer2023
37940695Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.Cell Discov2023
37023452Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer.Obstet Gynecol2023
37218522Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer.Analyst2023
36948527Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.Int J Gynecol Cancer2023
37311055A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.Oncologist2023
37274180Endothelial p130cas confers resistance to anti-angiogenesis therapy.Cell Rep2023
37100807Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.Nat Commun2023
37478190Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.Sci Adv2023
37031740Enhancing oral delivery of plant-derived vesicles for colitis.J Control Release2023
37326992Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.JAMA Netw Open2023
36884347RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.Cell Rep2023
36853778SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.Mod Pathol2023
36835335Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.Int J Mol Sci2023
36907533Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.Am J Obstet Gynecol2023
36423446Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.Gynecol Oncol2023
36930815Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.Cancer2023
36824283Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer.iScience2023
34772589CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.Cell Signal2022
35545008Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.Mol Cancer Ther2022
35732127Endothelial p130cas confers resistance to anti-angiogenesis therapy.Cell Rep2022
35606067The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Gynecol Oncol2022
35599168Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.Gynecol Oncol2022
35626102Platelets Increase the Expression of PD-L1 in Ovarian Cancer.Cancers (Basel)2022
35390531Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment.Pract Radiat Oncol2022
35688808Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.Nat Commun2022
36528667Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.J Transl Med2022
35965413Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.Mol Ther2022
36239936Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.JAMA Netw Open2022
35992327Race-associated molecular changes in gynecologic malignancies.Cancer Res Commun2022
36302510Antibody therapeutics for epithelial ovarian cancer.Expert Opin Biol Ther2022
35958027Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research.iScience2022
35892848Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer.Cancers (Basel)2022
36253486Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.Nat Cancer2022
35914489Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304].EBioMedicine2022
36251340Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.Cancer2022
36077735Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Cancers (Basel)2022
35252817Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.iScience2022
35094142Targeting CCR2<sup>+</sup> macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.J Cancer Res Clin Oncol2022
35216808Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.Gynecol Oncol2022
35326647Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer.Cancers (Basel)2022
35081345Endothelial p130cas confers resistance to anti-angiogenesis therapy.Cell Rep2022
35022962Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.Cancer Metastasis Rev2022
34670140The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions.Semin Cancer Biol2022
34608736Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer.J Thromb Haemost2022
33122243Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.Int J Gynecol Cancer2021
  • 1 - 50 of 765

Recommended Authors

George Au-Yeung
The University of Melbourne
Career Start Year 2012
Number of shared co-authors 11
Ruby Yun-Ju Huang
National Taiwan University College of Medicine
Career Start Year 2008
Number of shared co-authors 24
Boris Winterhoff
University of Minnesota
Career Start Year 2008
Number of shared co-authors 34
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 27
Shin-Wha Lee
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 2006
Number of shared co-authors 1
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 2
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 25
Sven Mahner
University Hospital
Career Start Year 2002
Number of shared co-authors 25
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 7
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 15
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Career Start Year 2000
Number of shared co-authors 36
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 28
Paul Haluska
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 29
Jacqueline F Donoghue
University of Melbourne
Career Start Year 1995
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 4
Yong-Man Kim
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1994
Number of shared co-authors 3
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 6
Rosalind Glasspool
University of Glasgow
Career Start Year 1992
Number of shared co-authors 32
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 3
Gustavo C Rodriguez
Clinica Quirurgica 2 (Surgical Clinic 2), Hospital Maciel
Career Start Year 1990
Number of shared co-authors 40
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 15
Francesco Caiazza
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1987
Number of shared co-authors 0
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 0
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 36
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 6
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 41
Anna DeFazio
Westmead Hospital
Career Start Year 1972
Number of shared co-authors 47

Collaborators

Cristina Ivan
The University of Texas MD Anderson Cancer Center
Co-authored papers 79
Rajesha Rupaimoole
Harvard Medical School, Beth Israel Deaconess Medical Center
Co-authored papers 61
Aparna A Kamat
Houston Methodist Hospital
Co-authored papers 41
Prahlad T Ram
Co-authored papers 36
Chad V Pecot
University of North Carolina at Chapel Hill
Co-authored papers 34
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Co-authored papers 32
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 26
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 22
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Co-authored papers 21
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Co-authored papers 21
Jeong-Won Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Co-authored papers 20
Kathleen M Schmeler
The University of Texas MD Anderson Cancer Center
Co-authored papers 17
Michael J Birrer
Co-authored papers 16
Charlotte C Sun
Co-authored papers 15
Mien-Chie Hung
Co-authored papers 15
Da Yang
Co-authored papers 14
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 12
Yiling Lu
Co-authored papers 12
Ilya Shmulevich
Institute for Systems Biology
Co-authored papers 11
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 10
Limei Hu
Aier Eye Hospital of Wuhan University
Co-authored papers 10
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 9
David Cogdell
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 6
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Adrian L Harris
University of Oxford
Co-authored papers 6
Jun Yao
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers 5
Release 1.2